Mechanistic analysis of combination IFB-a2b chlorpheniramine, ibuprofen

Chlorphenamine is a known antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis, whereas Ibuprofen is a potent nonsteroidal anti-inflammatory drug (NSAID). Combination of Chlorpheniramine and ibuprofen combination have long been postulated to treat common cold and its symptoms. Role and efficacy in the COVID-19 remains to be elucidated. Explore the […]

Mechanistic analysis of Acalabrutinib (Calquence)

Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. […]

Adverse Event considerations for repositioning remdesivir, hydroxychloroquine, chloroquine, and interleukin (IL)-6 inhibitors in COVID-19 patients

Patients with COVID-19 often also face cardiovascular challenges and associated comorbidities. Understanding how repositioned drugs to treat COVID-19 may impact the cardiovascular health of patients is important.Live Graph Detail: Targets of the drugs are included (e.g. RNA dependent RNA polymerase, target of remdesivir, IL-7, target of IL-6 inhibitors). Explore the live graph.

Targeting the RAS system against COVID-19

There is growing amount of evidence to suggest the use of pharmaceuticals that target the Renin-Angiotensin System (e.g. angiotensin 1-7, ARBs and ACE inhibitors) may be beneficial in the treatment of COVID-19. This graph shows the interconnections among these classes of drugs, and SARS-CoV-2 via key genes implicated in this pathway. mediated. Explore the live […]